Details
Category: Volume 08 Issue 10 October 2020
Hits: 2312

Title: Artesunate: an Artemisinin Derivative having Antiviral Properties with Multiple Pleotropic Effects is a Perfect Potential Agent for the Treatment of Symptomatic  COVID-19 Infection and Related Hyper inflammation States

Authors: Dr (Prof.) Butungeshwar Pradhan, Dr (Asst. Prof.) Bikash Chandra Nanda, Dr Gourav Pradhan

 DOI: https://dx.doi.org/10.18535/jmscr/v8i10.34

Abstract

Artemisinin are not limited to the treatment of malaria, and  wealth of studies demonstrating the activity of artemisinin and its derivatives against cancer cells, anti-inflammatory effects against SLE, RA, allergic asthma and as  antiviral agent in various viral diseases including single stranded RNA virus Hepatitis C. Artesunate has concentration dependent killing effects on malaria and other viral infections with autoinduction of its own metabolism. Thus, initial high IV doses, short course of Artesunate therapy may be very useful as an antiviral agent in the treatment of COVID-19 infection. Artemisinin class of compounds have several multiple beneficial effects that are important for different diseases, might be more versatile and more successful. Artesunate a multifunctional molecule with favourable PK/PD characteristics, is a perfect potential option for urgent treatment of symptomatic COVID-19 infection. Due to its anti-inflammatory, immunomodulatory, antioxidant, anticytokine, multiorgan protective properties and antiviral activity against wide varieties of viruses including SARS-CoV-2 in-vitro. It has also synergistic effects with other antiviral drugs; decreases viral replication and decreases TNF-α and IL-6 levels, which are key in COVID-19 induced cytokine storm and ARDS.

Keywords: Artesunate, Antiviral, COVID-19, Anti-inflammatory, Anticytokine, immunomodulatory, Antioxidant, IL-6, TNF-α.

References

  1. Yujun Tang, Jiajia Liu, Dingyi Zhang, Zhanghao Yu, Jinjun Ji, Changping Wen. Cytokine storm in COVID-19: The current Evidence and treatment strategies. Frontiers in Immunology. 2020; 11:1708. doi.10.3389/fimmu.2020.01708.
  2. Sarah D Alessandro, Diletta Seaccabarozzi, Lucia Signorini, Fedrica Perogo, Denise P Ilboudo et al. The use of antimalarial drugs against viral infection. Microorganism. 2020;8;85.doi.10.3390/microorganism. 80/0085.www.mdpi.com/journal/microorganism.
  3. Tuğçenur Uzun, Orcun Toptas. Artesunate: could be an alternative drug to chloroquine in COVID‑19 treatment? Chinese Medicine. (2020) 15:54. https://doi.org/10.1186/s13020-020-00336-8.
  4. H Xu,Y He,X Yang, L Liang, Z Zhang,Y Ye,X Yang,F Lian,L Sun. Antimalarial Agent Artesunate Inhibit TNF-α-induced Production of Proinflammatory Cytokines via Inhibition of NF-kβ and P13Kinase/Akt Signal Pathway in Human Rheumatoid Arthritis Fibroblast-like Synoviocytes. Rheumatology.2007;46:920-926.
  5. Wenosch C, Linnau KF,et al.Plasma level of the IL-6 found persistently with plasmodium falciparum malaria.J Infect Dis. 1999;179: 747-750.
  6.  L Jiang, et al. Artesunate attenuates lung injury in paraquat intoxicated rats via downregulation of inflammatory cytokines. Cli Lab.2015; 61(11):1601-1607).
  7. Chang Cheng, W. Eugene Ho, Fera Y. Goh, Shou Ping Guan, Li Ren Kong, et al. Anti-Malarial Drug Artesunate Attenuates Experimental Allergic Asthma via Inhibition of the Phosphoinositide 3-Kinase/Akt Pathway. PLoS ONE. June 2011; 6 (6):  e20932. www.plosone.org.
  8. Mei Kuang, Yanyan Cen, Rongxin Qin, Shenglan Shang, Zhaoxia Zhai.  et al. Artesunate Attenuates Pro-Inflammatory Cytokine Release from Macrophages by Inhibiting TLR4-Mediated Autophagic Activation via the TRAF6-Beclin1-PI3KC3 Pathway. Cell Physiol Biochem 2018; 47:475-488.  DOI: 10.1159/000489982.
  9.  Dorothy HJ Cheong, Danel WS Tan, Fred WS Wong, Thai Tan. Antimalarial drug artemisinin and its derivatives for the treatment of respiratory diseases. Pharmacological Research.2020; 158: 104901.
  10. Thomas Efferth, Marta R, Romero, Dano G Wolf, Thomas Stamminger, Jose J, G Mann. The antiviral Activities of Artemisinin and Artesunate .Clinical Infectious Disease.2008; 47; 804-811.
  11.  Rong Jun Wan, Yue Hong Li.  Effects of Artesunate prevent nephritis via the Toll‑like receptor 4/nuclear factor‑κB signaling pathway in rats. Molecular Medicine Reports 16: 6389-6395, 2017. Doi: 10.3892/mmr.2017.7362.
  12. Lin Y,Wu F,Xie Z,Song X,Zhu X,Zhu Q, Wei J,Tan S,Liang L.Ging B L. Clinical study of artesunate in the treatment of coronavirus disease 2019.Europe PMC. 01 Apr 2020, 32(4):417-420. DOI: 10.3760/cma.j.cn121430-20200312-00412. PMID: 3252734.
  13. Skinner TS, Manning LS, Johnston WA, Davis TM. In vitro stage specific sensitivity of plasmodium falciparum to quinine and artemisinin drugs. Inf J Parsite.1996; 26:519-525.
  14. Clinical Monograph. Aretesunate. An advance in malaria management. Scientific communication.1996;ISBN Scientific communication.962-524.©33-0
  15. Alin MH, Bjorkman A. Concentration and time dependence of artemisinin efficacy against plasmodium falciparum in vitro. AM J Trop Med Hyg.1994; 50; 771-776.
  16.  Li Q, Milhous WK, Weina PJ. Fatal neurotoxicity of artemisinin derivatives is related to drug pharmacokinetics profiles in animal species. Curr Topic Toxicol.2006; 3:1-16.
  17. White NJ. Clinical pharmacokinetics and pharmacodynamics of artemisinin and its derivatives. Trans R Soc Trop Med Hyg.1994; 88 :( suppl-1) S41-43.
  18. Ilett, KF, Batty KT. Powell S. M Binh, T Q, Thu l., Phuong HL, Hung NC,Davis TM. The pharmacokinetic properties of intramuscular artesunate and rectal Dihydroartemisinine in uncomplicated falciparum malaria. Br. J. Clin. Pharmacol.2002; 53, 23−30.  
  19. Hien TT, Davis TM, Chuog LV et al. Comparative pharmacokinetics of intramuscular artesunate and artemeether in patients with severe falciparum malaria. Antimicrob Agents Chemother.2004; 48:4234-4239.
  20. Suputtamanskhoi Y, Newton PN, Angus B, Tejaisavadharm P. et al. A comparison of oral artesunate and artemether antimalarial bioavailability in acute falciparum malaria.Br J Cli Pharmacol.2001;52:655-661.
  21. Tiang JB, Li GQ; Guo, XB Kong YC. Antimalarial activity of mefloquine and qinghaosu. Lancet. Sat. Aug.1982; 2:285-288.
  22. White NJ. Antimalarial pharmacokinetics and treatment regimens.1992; 34:1-10.
  23. Gordi T, Xie R, Huong NV, Huong DX, Karlsson MO, Ashton M. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first pass hepatic extraction. Br J Clin Pharmacol .2005; 59:189–98.
  24. Ashtan M,Hai TN, Sy ND, Huang, DX, Van Huang N, Nieu NJ, Cong LD. Artemisinin pharmacokinetics is time dependent during repeated oral administration in healthy male adults. Drug Metab Dispos.1998;26:25-27.
  25. Khanh, NX;de Vries , PJ Ha, LD Van, Boxtel CJ, Koopmans R, Kager PA. Decline concentrations of Dihydroartemisinine in plasma during 5-day oral treatment with artesunate for falciparum malaria. Antimicrob Agents Chemother .1999; 43:690-692.
  26.  Barradell LB, Fitton A. Artesunate: a review of its pharmacology and therapeutic efficacy in treatment of malaria. Drugs 1995; 50:714–41.
  27.  Li QC, Mog SR, Si YZ, Kyle DE, Gettayacamin M, Milhous WK. Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents. Am J Trop Med Hyg 2002; 66:516-25.
  28.  van Hensbroek MB, Onyiorah E, Jaffar S, et al. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med 1996; 335: 69–75.
  29. Dondorp A, Nosten F, Stepniewska K, Day N,  White N; South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) Group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366:717–2
  30. Karbwang  J; Na-Bangchang  K, Thanavibut A, Molunto P. Plasma concentrations of artemether and its major plasma metabolite Dihydroartemisinine following a 5 day regimen of oral artemether  in patients with uncomplicated falciparum malaria. Ann Trop Med Parsit.1998; 92:31-36
  31. Li Q,  Xie LH; Haeberle  A, Zhang  J, Weina P. The evaluation of radiolabeled artesunate in tissue distribution in rats and protein binding in human. Am J Trop Med Hyg.1006; 75:817-826.
  32. Li Q , Milhous WK, Weina PJ. Artemisinin in malaria therapy. Overseas press (India) Pvt. Ltd. First Edn.2003.p-10, 82, 84,98.
  33. YM Bar-On, A Flamholz, R Phillips, R Milo. Science Forum .SARS-CoV-2 (COVID-19) by the numbers. eLife.2020; 9:e57309. DOI https://doi.org/10.7554/eLife.57309.p- 1- 15.
  34. Pradhan B. Some considerations in antimalarial chemotherapy of severe falciparum malaria.  J Evid Based Med Healthc.2017; 4(13):743 748. doi.10.18410/jebmh/2017/144.
  35. Ruiyuan Cao, Hengrui Hu,Yufeng Li, Xi Wang, Mingyue Xu, Jia Liu. et al.Anti-SARS-CoV-2 Potential of Artemisinins In- Vitro. ACS Infect Dis. July 31,2020. https://dx.doi.org/10.1021/acsinfecdis.0c00522.
  36. Dr Butungeshwar Pradhan et al. Edaravone: A Free Radical Scavenger with Multiple Pleotropic Actions can be a Potential Game Changer Agent in Prevention and Alleviation of COVID-19 – Induced Cytokine Storm. JMSCR. July 2020; 8 (7): P- 227- 236.

Corresponding Author

Dr (Prof.) Butungeshwar Pradhan

VSSIMSAR, Burla, Sambalpur, Odisha, India Pin-768017